SMTL ID : 8u1f.1

FGFR2 Kinase Domain Bound to Irreversible Inhibitor Cmpd 10

Coordinates

PDB Format

Method

X-RAY DIFFRACTION 3.33 Å

Oligo State

homo-dimer

Ligands

1 x GOL: GLYCEROL(Non-functional Binders)

GOL.1: 11 residues within 4Å: Chain A: G.10, V.11, S.12, E.15, P.17, L.76, V.80, T.103, G.106, P.107, L.108 2 PLIP interactions: 2 interactions with chain A Hydrogen bonds: A:G.10, A:G.10

2 x UIM: N-[4-(4-amino-7-methyl-5-{4-[(4-methylpyrimidin-2-yl)oxy]phenyl}-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenyl]-2-methylpropanamide(Covalent)

UIM.2: 27 residues within 4Å: Chain A: L.35, G.36, E.37, G.38, C.39, F.40, V.43, A.63, K.65, E.82, M.85, M.86, I.96, V.112, E.113, Y.114, A.115, N.119, R.173, D.174, R.178, N.179, L.181, A.191, D.192, F.193, G.194 14 PLIP interactions: 14 interactions with chain A Hydrophobic interactions: A:L.35, A:F.40, A:F.40, A:V.43, A:E.82, A:R.178, A:L.181, A:L.181, A:A.191 Hydrogen bonds: A:E.37, A:K.65, A:E.82, A:A.115 pi-Stacking: A:F.193 UIM.4: 23 residues within 4Å: Chain B: L.35, G.36, E.37, G.38, C.39, F.40, V.43, A.63, K.65, E.82, M.86, I.96, V.112, E.113, Y.114, A.115, N.119, R.178, N.179, L.181, A.191, D.192, F.193 13 PLIP interactions: 13 interactions with chain B Hydrophobic interactions: B:F.40, B:V.43, B:V.43, B:V.112, B:R.178, B:L.181, B:L.181, B:A.191, B:F.193 Hydrogen bonds: B:E.37, B:E.113, B:A.115, B:N.179

1 x SO4: SULFATE ION(Non-functional Binders)

SO4.3: 6 residues within 4Å: Chain B: P.220, L.264, K.265, G.267, R.269, A.290 2 PLIP interactions: 2 interactions with chain B Hydrogen bonds: B:G.267 Salt bridges: B:R.269

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Schonherr, H. et al., Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2. Proc.Natl.Acad.Sci.USA (2024)

Release Date

2024-02-14

Peptides

Fibroblast growth factor receptor 2: AB

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

B
B

Fibroblast growth factor receptor 2

Related Entries With Identical Sequence